Anika Therapeutics (ANIK-Q) Stock Price and News - The Globe and Mail

Add to Watchlist Create Alerts

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

Day Low27.53

Day High28.19

Open:27.91

Previous Close

52-Week High/Low

Volume

Average Volume

Price/Earnings (TTM)

Forward Annual Dividend & Yield

Market Capitalization, $M

5-Day Change

Realtime quote and/or trade prices are not sourced from all markets.

Sidoti's Small-Cap Virtual March Conference

Anika Reports Second Quarter Fiscal 2022 Financial Results

Anika Receives the ACE Award for Cutting-Edge Innovation for Tactoset® Injectable Bone Substitute from the American Orthopedic Society for Sports Medicine

Anika to Issue Second Quarter 2022 Financial Results on Wednesday, August 3, 2022

Sidoti's Summer Small Cap Virtual Conference

Anika to Participate in the Sidoti Small Cap Virtual Investor Conference

Anika Receives FDA 510(k) Clearance for the X-Twist™ Knotless Fixation System, Expanding its Sports Medicine Soft Tissue Portfolio

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Anika to Participate in the UBS Global Healthcare Conference 2022

Anika Reports First Quarter Fiscal 2022 Financial Results

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Anika to Issue First Quarter 2022 Financial Results on Thursday, May 5, 2022

Anika to Participate in the 21st Annual Needham Virtual Healthcare Conference

Anika to Showcase its Transformation into a Global Leader in Joint Preservation during the 2022 AAOS Annual Meeting

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Anika to Participate in the Canaccord Genuity Musculoskeletal Conference

Anika Reports Fourth Quarter and Year-End 2021 Financial Results

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 11, 2022

Anika to Issue Fourth Quarter and Year-End 2021 Financial Results on Tuesday, March 8, 2022

February 8, 2022

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 10, 2021

Anika to Participate in Upcoming Investor Conferences

November 18, 2021

Anika Appoints Sheryl Conley to Board of Directors

November 1, 2021

Anika Launches the WristMotion® Total Wrist Arthroplasty System at the American Society for Surgery of the Hand Annual Meeting

September 30, 2021

Tactoset® Injectable Bone Substitute Now FDA Cleared for Hardware Augmentation

September 14, 2021

Anika to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

September 7, 2021

Anika to Debut Joint Preservation Portfolio at the 2021 AAOS Annual Meeting

September 1, 2021

Anika Reports Second Quarter 2021 Financial Results

Anika to Issue Second Quarter 2021 Financial Results on Thursday, August 5, 2021

First Anika WristMotion® Total Wrist Arthroplasty Surgery Performed

Anika Hosts 2021 Virtual Investor Day

Anika to Host its 2021 Virtual Investor Day on June 3, 2021

Anika Reports First Quarter 2021 Financial Results

Profile

Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.